| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03472560 2017-004345-24 Details | 2024-04-09 Interventional | 2 | 61 | Avelumab Axitinib Carcinoma, Non-… Lung Neoplasms Non-Small Cell … Urothelial Canc… | The study was terminated since there was no need for further safety or efficacy data to be
collected. The participants having benefit from the Investigational treatments have been moved
to a continuation study (NCT05059522) - | |||
| NCT03428945 Details | 2024-04-09 Interventional | 2 | 273 | Hydroxychloroqu… Diabetes Mellit… Diabetes Mellit… Type1 Diabetes … | This trial has undergone a prespecified interim analysis which determined that this treatment
provides no statistically significant delay in the onset of abnormal glucose tolerance or Type
1 Diabetes. Interim analysis completed prompted the DSMB's decision to terminate the protocol early limiting the originally planned follow up period for participants. | |||
| NCT02401035 2014-002182-29 Details | 2024-04-09 Interventional | 4 | 19 | Pantoprazole Gastroesophagea… Gastroesophagea… | Study was terminated early due to the infeasibility of enrolling the required number of
participants per protocol in the 1 <2 years of age cohort. - | |||
| NCT05411094 Details | 2024-04-08 Interventional | 1 | - | Antibodies, Mon… Durvalumab Immunoglobulin … Immunoglobulins Olaparib Poly(ADP-ribose… Carcinoma Pancreatic Neop… Locally Advance… Stage II Pancre… Stage III Pancr… Unresectable Pa… | Scheduled Interim Monitoring - | |||
| NCT05304663 Details | 2024-04-08 Interventional | 1 | 0 | Lomustine Glioblastoma | The Sponsor had no further plan for the study in object - | |||
| NCT03878095 Details | 2024-04-08 Interventional | 2 | - | Olaparib Poly(ADP-ribose… Cholangiocarcin… Neoplasms Malignant Solid… Refractory Chol… Refractory Mali… | Other - Pending Data Analysis - | |||
| NCT03712605 Details | 2024-04-08 Interventional | 3 | - | Pembrolizumab Carcinoma Carcinoma, Merk… Pathologic Stag… Pathologic Stag… Pathologic Stag… | Other - Reached planned accrual; increase being considered - | |||
| NCT03317392 Details | 2024-04-08 Interventional | 1/2 | - | Olaparib Poly(ADP-ribose… Radium Ra 223 d… Prostatic Neopl… Castration-Resi… Metastatic Pros… Stage IVB Prost… | Other - evaluation of enrolled patients - | |||
| NCT05265208 2021-001575-16 Details | 2024-04-05 Interventional | 2 | - | Capecitabine Cholangiocarcin… Resectable Intr… | 1st level of sequential inclusion reached - | |||
| NCT05261490 Details | 2024-04-05 Interventional | 1/2 | 10 | Doxorubicin Liposomal doxor… Carcinoma Carcinoma, Ovar… Fallopian Tube … Ovarian Neoplas… Epithelial Ovar… Fallopian Tube … Ovarian Cancer Ovarian Carcino… Primary Periton… | A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this
study for administrative reasons. The reason for study termination is not due to any safety
concerns or requests from regulatory authorities. - | |||
| NCT01938547 Details | 2024-04-05 Interventional | 4 | 0 | Clevidipine Pediatric Perio… | Sponsor Decision - | |||
| NCT04984759 Details | 2024-04-04 Interventional | 4 | 0 | Primaquine Tafenoquine Healthy Lactati… | Local EC requested that the arms of study be submitted as separate protocols so they could
respond to the different risk of each arm. In response investigators have withdrawn this
protocol and begun separate submissions, starting with NCT06191458. - | |||
| NCT04936841 Details | 2024-04-04 Interventional | 2 | 5 | Pembrolizumab Carcinoma, Squa… Squamous Cell C… Head and Neck C… | study closed by the sponsor Study terminated early by the sponsor | |||
| NCT04604132 Details | 2024-04-04 Interventional | 1/2 | 47 | Albumin-Bound P… Antibodies, Mon… Paclitaxel Ramucirumab Adenocarcinoma Gastric Adenoca… | Terminated prematurely for administrative reasons not related to patient safety. - | |||
| NCT04602494 Details | 2024-04-04 Interventional | 4 | 5 | Varenicline Tobacco Use Dis… Nicotine Depend… Vaping | The pilot study used apo-varenicline under temp FDA authorization. When varenicline was
available an IND exemption was granted to enroll children, IRB approved a trial of varenicline
in participants ages 16-25 June 27, 2022, the pilot was terminated - | |||
| NCT05327361 Details | 2024-04-03 Interventional | 2 | 13 | Sunscreening Ag… Hyperpigmentati… Acne Post Inflammato… | Enrollment timeline ended - | |||
| NCT05261139 Details | 2024-04-03 Interventional | 2/3 | - | Nirmatrelvir Ritonavir COVID-19 | Recruitment was paused to allow time for further pharmacokinetic modelling and simulation work
to be performed to determine further dose regimens and PK blood sampling. No safety concerns
have been observed in participants enrolled to date. - | |||
| NCT04616560 Details | 2024-04-03 Interventional | 2 | - | Camptothecin Immunoconjugate… Trastuzumab Trastuzumab der… Osteosarcoma Recurrence Recurrent Osteo… | Other - Stage 1 has met accrual - | |||
| NCT04543188 2022-003184-23 Details | 2024-04-03 Interventional | 1 | 65 | Midazolam Brain Neoplasms Carcinoma, Non-… Melanoma Neoplasms Brain Neoplasms… Malignant Melan… Malignant Neopl… | Pfizer has made an internal business decision to not continue further development of
PF-07284890. This decision was not due to major safety concerns or requests from any regulatory
authorities. - | |||
| NCT04476797 Details | 2024-04-03 Interventional | 1/2 | 47 | Manganese Carcinoma, Non-… NSCLC Non-metastatic SBRT | Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due
to meeting the requirements of a futility analysis Study was terminated early by the Sponsor based on a the results of a futility analysis that was conducted on another program and the Sponsor decided to terminate the develop of GC4711. The last randomized subject did not complete protocol therapy but was followed for safety for a period of 30 days post the last administration of GC4711/Placebo +SBRT. |